1. Metabolic Disease

Metabolic Disease

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2797
    Chitinase, Serratia marcescens 9001-06-3
    Chitinase, Serratia marcescens (EC 3.2.1.14) has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer).
    Chitinase, Serratia marcescens
  • HY-P2932
    Cholecystokinin 9011-97-6 99.85%
    Cholecystokinin is a peptide hormone. Cholecystokinin, as a hunger suppressant, inhibits food intake and stimulates the digestion of fat and protein. Cholecystokinin can be used for the research of gastrointestinal system.
    Cholecystokinin
  • HY-Y1718
    Tridecanoic acid 638-53-9 ≥98.0%
    Tridecanoic acid (N-Tridecanoic acid), a 13-carbon medium-chain saturated fatty acid, can serve as an antipersister and antibiofilm agent that may be applied to research bacterial infections. Tridecanoic acid inhibits Escherichia coli persistence and biofilm formation.
    Tridecanoic acid
  • HY-Y1819
    2-Acetonaphthone 93-08-3 99.89%
    2-Acetonaphthone is an endogenous metabolite.
    2-Acetonaphthone
  • HY-101406
    Thyroxine sulfate 77074-49-8 ≥98.0%
    Thyroxine sulfate is a thyroid hormone metabolite.
    Thyroxine sulfate
  • HY-107532
    N-Nonyldeoxynojirimycin 81117-35-3 ≥99.0%
    N-Nonyldeoxynojirimycin (NN-DNJ) is a potent inhibitor of alpha-glucosidase and alpha-1,6-glucosidase (IC50s, 0.42, 8.4 μM, respectively), inhibits glycogen breakdown.
    N-Nonyldeoxynojirimycin
  • HY-112132
    Palmitodiolein 2190-30-9 ≥99.0%
    Palmitodiolein (Triglyceride POO) is a triacylglycerol which is present in vegetable oils.
    Palmitodiolein
  • HY-113447
    11-Dehydrocorticosterone 72-23-1
    11-Dehydrocorticosterone is a endogenous corticosteroid. 11-Dehydrocorticosterone can be a source of transcriptionally active glucocorticoid in cardiac myocytes and fibroblasts. 11-Dehydrocorticosterone can increase SGK mRNA expression in cardiac fibroblast.
    11-Dehydrocorticosterone
  • HY-116175
    BIBB 515 156635-05-1 ≥99.0%
    BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED50 values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL).
    BIBB 515
  • HY-119678
    Fortunellin 20633-93-6
    Fortunellin, is a flavonoid, that can be isolated from the fruits of Fortunella margarita (kumquat). Fortunellin exhibits little toxicity to mice and suppresses inflammation and ROS generation in H9C2 cells induced by LPS. Fortunellin protects against fructose-induced inflammation and oxidative stress by enhancing AMPK/Nrf2 pathway. Fortunellin can be used for diabetic cardiomyopathy research.
    Fortunellin
  • HY-121885
    LMD-009 950195-51-4 99.35%
    LMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC50s from 11 to 87 nM.
    LMD-009
  • HY-123593
    Mozavaptan hydrochloride 138470-70-9 99.89%
    Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
    Mozavaptan hydrochloride
  • HY-124265
    4β-Hydroxycholesterol 17320-10-4 ≥98.0%
    4β-hydroxy Cholesterol is a major oxysterol cholesterol metabolite and a precursor in the synthesis of bile acids that is found in human circulation.
    4β-Hydroxycholesterol
  • HY-124418
    SBI-477 781628-99-7 ≥98.0%
    SBI-477 is a chemical probe stimulated insulin signaling by deactivating the transcription factor MondoA, leading to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain–containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes.
    SBI-477
  • HY-128661
    IDH1 Inhibitor 2 2244895-42-7 99.40%
    IDH1 Inhibitor 2 (compound 13) is a potent wild-type IDH1 inhibitor via a direct covalent modification of His315, with an IC50 of 110 nM.
    IDH1 Inhibitor 2
  • HY-128933
    AMP-PNP tetralithium 72957-42-7
    AMP-PNP tetralithium (Adenylyl-imidodiphosphate tetralithium) is a non-hydrolysable analogue of ATP and inhibits KATP channels.
    AMP-PNP tetralithium
  • HY-135841
    CM010 692269-09-3 99.70%
    CM010 is a potent and selective aldehyde dehydrogenase 1A (ALDH1A) family inhibitor, with IC50s of 1700, 740, and 640 nM for ALDH1A1, ALDH1A2, and ALDH1A3, respectively. CM010 does not inhibit any of the other ALDH family members. CM010 can regulate metabolism and has anti-cancer activity.
    CM010
  • HY-137258
    (±)-N-3-Benzylnirvanol 93879-40-4 99.88%
    (±)-N-3-Benzylnirvanol is a racemic mixture of (+)-N-3-Benzylnirvanol and (-)-N-3-Benzylnirvanol. (+)-N-3-Benzylnirvanol and (–)-N-3-Benzylnirvanol are potent and selective cytochrome P450 inhibitors with Ki values of 0.25 and 5.3 μM for CYP2C19, respectively.
    (±)-N-3-Benzylnirvanol
  • HY-137813
    PERK-IN-4 1337531-89-1 98.30%
    PERK-IN-4 is a potent and selective PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC 50 of 0.3 nM. PERK is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states.
    PERK-IN-4
  • HY-145542
    Isovalerylcarnitine chloride 139144-12-0 ≥98.0%
    Isovalerylcarnitine chloride, a product of the catabolism of L-leucine, is a potent activator of the Ca2+-dependent proteinase (calpain) of human neutrophils.
    Isovalerylcarnitine chloride
Cat. No. Product Name / Synonyms Application Reactivity